Bruce Carleton, PharmD, FCP, FISPE
Bruce Carleton is Professor and Chair, Division of Clinical Pharmacology, Department of Pediatriics, University of British Columbia. He is a Senior Clinician Scientist at the BC Children’s Hospital Research Institute. He is also the CEO of the Canadian Pharmacogenomics Network for Drug Safety. He has a keen interest in advancing the safe and effective use of drugs, particularly in children. He is passionate about caring for kids.
Alastair Cribb, DVM, PhD
Alastair Cribb is Professor of Clinical Pharmacology in the Faculty of Veterinary Medicine and adjunct professor in the Faculty of Medicine at the University of Calgary. Dr. Cribb's primary research interests are in the molecular basis of individual and species difference in response to drugs and other xenobiotics. He has a particular interest in idiosyncratic drug reactions.
Jorge Ganopolsky, PhD
Dr. Ganopolsky is Manager of Scientific Affairs at Dynacare Next. Dr. Ganopolsky works in the development and commercialization of specialized diagnostic tools for personalized medicine in order to provide actionable solutions for patients and healthcare providers. He has performed research in blood coagulation, inflammation, wound healing and in the role of the microbiome in metabolic disorders both in academia and industry settings.
Colin Ross, PhD
Colin Ross’s research aims to save and improve the lives of patients by developing new safer and more effective therapeutic options for patients based upon an individual’s genetic blueprint. Adverse drug reactions are a striking problem. In the treatment of childhood cancer, for example, 42% of patients develop permanently disabling or life-threatening adverse drug
Nasir Afsar (Pakistan)
Marc Chretien (ON)
Alastair Cribb (AB)
Anne Dittrich (The Netherlands)
Jorge Ganopolsky (QC)
Michelle Hildebrandt (Houston)
David Lee (ON)
Don Miller (MB)
Colin Ross (BC)